Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.
CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.
Read moreThe PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!
Read morePharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager
Read moreBy using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
Awesome 👌Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.
Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.
PharmNovo at Biostock
CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.
Read more →Seasons Greetings 2022
The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!
Read more →Strengthening the team
PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager
Read more →